CytoMed Therapeutics Limited (GDTC) Stock

CytoMed Therapeutics Limited, a pioneering pre-clinical biopharmaceutical firm headquartered in Singapore, specializes in the advancement of innovative cell-based immunotherapies designed to combat human cancers. At the forefront of its research efforts is CTM-N2D, the company's leading product candidate. CTM-N2D features expanded gamma delta T cells engineered with chimeric antigen receptors targeting natural killer group 2D ligands, aimed at enhancing cytotoxicity against cancerous cells.

In addition to CTM-N2D, CytoMed Therapeutics Limited is actively developing iPSC-gdNKT, utilizing induced pluripotent stem cells (iPSCs) to generate gdNKT cells. These synthetic hybrids combine the characteristics of gamma delta T cells and natural killer (NK) cells, offering a promising approach to broaden the scope of cancer treatment. Another promising candidate in its pipeline is CTM-GDT, which leverages expanded gamma delta T cells equipped with a multi-recognition system to detect and combat various types of cancers.

Since its establishment in 2018, CytoMed Therapeutics Limited has demonstrated a commitment to pushing the boundaries of cancer immunotherapy through innovative research and development. With a focus on leveraging cutting-edge biotechnologies, the company continues to advance its pipeline of therapeutic candidates, aiming to address unmet medical needs and improve outcomes for patients battling cancer worldwide.